Zevra Therapeutics EV/EBIT ZVRA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Oct 23, 2026: 2.9×
5-year median: 13.3×
Against its 5-year history: 0th; percentile: 0 is its lowest day, 100 its highest
5-year range: 2.9× to 67.1×
Peer median: 7.6×

Zevra Therapeutics' EV/EBIT is 2.9× as of Oct 23, 2026.

That is below its 5-year median of 13.3×, lower than on 100% of days in the last 5 years.

Over that time it ranged from 2.9× in Oct 2026 to 67.1× in Jun 2021.

The median for 10 large drugmakers of a similar size is 7.6×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.9×	2.9×	6.5×
2025	n/m a value too high to mean anything
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	4.6×	4.6×	23.8×
2021	24.2×	19.4×	67.1×

Against its peers

Companies in Drug Manufacturers - General nearest Zevra Therapeutics' size, closest first, today.

Company	EV/EBIT
ZVRAZevra Therapeutics	2.9×
IRWDIronwood Pharmaceuticals	3.5×
PBYIPuma Biotechnology	15.6×
CRMDCorMedix	2.3×
ARVNArvinas	n/m
COLLCollegium Pharmaceutical	9.4×
ABUSArbutus Biopharma	4.9×
AMPHAmphastar Pharmaceuticals	12.2×
OMEROmeros	n/m
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
Peer median	7.6×

Where Zevra Therapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Zevra Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.